Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1968 3
1969 1
1970 1
1972 1
1975 1
1976 1
1977 1
1978 2
1979 2
1983 2
1984 2
1986 1
1987 1
1988 1
1990 6
1991 2
1992 3
1993 1
1995 2
1996 6
1997 1
1998 4
1999 4
2000 2
2001 3
2002 2
2003 2
2004 6
2006 3
2007 4
2008 2
2009 1
2010 4
2011 3
2012 2
2013 1
2014 2
2015 3
2016 1
2017 2
2018 5
2019 2
2020 4
2021 4
2022 1
2023 4
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell'Osso B, Siracusano A, Clerici M, Bellomo A, Sani G, d'Andrea G, Chiaie RD, Conca A, Barlati S, Di Lorenzo G, De Fazio P, De Filippis S, Nicolò G, Rosso G, Valchera A, Nucifora D, Di Mauro S, Bassetti R, Martiadis V, Olivola M, Belletti S, Andriola I, Di Nicola M, Pettorruso M, McIntyre RS, di Giannantonio M; REAL-ESK Study Group. Martinotti G, et al. Among authors: belletti s. J Affect Disord. 2022 Dec 15;319:646-654. doi: 10.1016/j.jad.2022.09.043. Epub 2022 Sep 24. J Affect Disord. 2022. PMID: 36167246
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Martinotti G, Dell'Osso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M, Barlati S, Rosso G, Di Nicola M, Marcatili M, d'Andrea G, Cavallotto C, Chiappini S, De Filippis S, Nicolò G, De Fazio P, Andriola I, Zanardi R, Nucifora D, Di Mauro S, Bassetti R, Pettorruso M, McIntyre RS, Sensi SL, di Giannantonio M, Vita A; REAL-ESK Study Group. Martinotti G, et al. Bipolar Disord. 2023 May;25(3):233-244. doi: 10.1111/bdi.13296. Epub 2023 Jan 18. Bipolar Disord. 2023. PMID: 36636839 Free article.
Alternative Therapies in the Treatment of Atrial Fibrillation.
Lombardi F, Belletti S, Lomuscio A. Lombardi F, et al. Among authors: belletti s. J Atr Fibrillation. 2013 Apr 6;5(6):754. doi: 10.4022/jafib.754. eCollection 2013 Apr-May. J Atr Fibrillation. 2013. PMID: 28496826 Free PMC article. Review.
Novel Activity of a Synthetic Decapeptide Against Toxoplasma gondii Tachyzoites.
Giovati L, Santinoli C, Mangia C, Vismarra A, Belletti S, D'Adda T, Fumarola C, Ciociola T, Bacci C, Magliani W, Polonelli L, Conti S, Kramer LH. Giovati L, et al. Among authors: belletti s. Front Microbiol. 2018 Apr 20;9:753. doi: 10.3389/fmicb.2018.00753. eCollection 2018. Front Microbiol. 2018. PMID: 29731744 Free PMC article.
106 results